English

Interim report Q1, 2025: Strong performance in EMEA

Report this content

First quarter 

  • Sales of SEK 842 (841) million, an increase of 1% in local currencies and 0% in SEK. The growth in local currencies excluding discontinued business was 3%. 
  • Sales per region, in local currencies was +8% in EMEA, +14% excluding discontinued business, +9% in Americas and -15% in APAC. 
  • Sales per product groups, in local currencies excluding discontinued business was +6% in Consumables, -5% in Technologies and +4% in Genetics. 
  • Sales per product groups, in local currencies was +3% in Consumables, -6% in Technologies and +1% in Genetics. 
  • Gross margin increased to 57.4% (57.1). 
  • Earnings before depreciation and amortisation (EBITDA) decreased to SEK 257 (272) million, giving an EBITDA margin of 30.6% (32.4), affected by foreign exchange impact of SEK -13 (1) million. 
  • Operating cash flow amounted to SEK 69 million (198). 
  • Net income was SEK 100 (115) million, resulting in earnings per share of SEK 0.74 (0.85).


Gothenburg, April 24, 2025
VITROLIFE AB (publ)
Bronwyn Brophy O´Connor, CEO
 

This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 24-04-2025 08:00 CET.

Contact:
Helena Wennerström, acting CFO, phone: +4670 822 80 86

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

Vitrolife Group is a global provider of medical devices and genetic testing solutions. Our vision is to enable people to fulfil the dream of having a healthy baby. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. With 1,100 employees worldwide and headquarters in Gothenburg, Sweden, our products and services are available in over 125 countries through our direct presence and a network of distributors. Vitrolife AB (publ) is listed on Nasdaq Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452.Tel: +46 31 721 80 00. E-mail: info@vitrolife.com. Website: www.vitrolifegroup.com.
 

Subscribe

Documents & Links